secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ensysce Biosciences, Inc. (ENSC)
CIK:        0001716947
Form:       8-K
Filed at:   2024-08-30T23:59:59+00:00
Accession:  0001493152-24-034451
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ensysce Biosciences raises $5M in concurrent registered direct offering and warrant exercise
--------------------------------------------------------------------------------

- Gross proceeds of $5M from sale of 3.55M shares (or equivalents) at $0.47 per share and exercise of 7.2M outstanding warrants at reduced price.
- Concurrent private placement of unregistered Series A-3 and A-4 warrants to purchase up to 28.7M shares, exercisable after stockholder approval.
- Net proceeds to fund TAAP and MPAR programs and supplement recently announced $14M NIH grant for PF614-MPAR.
- Existing warrants from November 2023 amended to $0.47 exercise price effective upon closing; stockholder approval required.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1716947/000149315224034451/0001493152-24-034451-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1716947/000149315224034451/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-034451

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer